ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in
treating patients with castration-resistant prostate cancer that has spread to other places
in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular
growth in certain types of tumors, including castrate resistant prostate cancer. Enzalutamide
has been shown to block testosterone from reaching prostate cancer cells by binding to a
receptor on prostate cancer cells, called androgen receptors. This works similar to a lock
and key. When enzalutamide (key) inserts into the androgen receptor (lock) testosterone
cannot attach to the androgen receptor, which slows the growth of tumor cells and may cause
them to shrink. Pembrolizumab is a monoclonal antibody (proteins that can protect the body
from foreign organisms, such as bacteria and viruses) designed to block a specific control
switch which may be activated by tumor cells to overcome the body's natural immune system
defenses. It also enhances the activity of the body's immune cells against tumor cells. The
purpose of this study is to find out the effects ZEN-3694, enzalutamide, and pembrolizumab on
patients with metastatic castration-resistant prostate cancer who have previously experienced
disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Rahul Aggarwal
Collaborators:
Merck Sharp & Dohme Corp. U.S. Army Medical Research and Development Command Zenith Epigenetics